Filiopoulos Vassilis, Boletis John N
Vassilis Filiopoulos, John N Boletis, Department of Nephrology and Transplantation Unit, Laiko University Hospital, 11527 Athens, Greece.
World J Transplant. 2016 Mar 24;6(1):103-14. doi: 10.5500/wjt.v6.i1.103.
The growing gap between demand and supply for kidney transplants has led to renewed interest in the use of expanded criteria donor (ECD) kidneys in an effort to increase the donor pool. Although most studies of ECD kidney transplantation confirm lower allograft survival rates and, generally, worse outcomes than standard criteria donor kidneys, recipients of ECD kidneys generally have improved survival compared with wait-listed dialysis patients, thus encouraging the pursuit of this type of kidney transplantation. The relative benefits of transplantation using kidneys from ECDs are dependent on patient characteristics and the waiting time on dialysis. Because of the increased risk of poor graft function, calcineurin inhibitor (CNI)-induced nephrotoxicity, increased incidence of infections, cardiovascular risk, and malignancies, elderly recipients of an ECD kidney transplant are a special population that requires a tailored immunosuppressive regimen. Recipients of ECD kidneys often are excluded from transplant trials and, therefore, the optimal induction and maintenance immunosuppressive regimen for them is not known. Approaches are largely center specific and based upon expert opinion. Some data suggest that antithymocyte globulin might be the preferred induction agent for elderly recipients of ECD kidneys. Maintenance regimens that spare CNIs have been advocated, especially for older recipients of ECD kidneys. CNI-free regimens are not universally accepted due to occasionally high rejection rates. However, reduced CNI exposure and CNI-free regimens based on mammalian target of rapamycin inhibitors have shown acceptable outcomes in appropriately selected ECD transplant recipients.
肾移植供需差距的不断扩大,引发了人们对使用扩大标准供体(ECD)肾脏的新兴趣,以努力增加供体库。尽管大多数关于ECD肾移植的研究证实,与标准标准供体肾脏相比,其同种异体移植物存活率较低,总体结果也较差,但ECD肾脏受者与等待透析的患者相比,存活率普遍有所提高,因此鼓励开展此类肾移植。使用ECD肾脏进行移植的相对益处取决于患者特征和透析等待时间。由于移植肾功能不佳、钙调神经磷酸酶抑制剂(CNI)诱导的肾毒性、感染发生率增加、心血管风险和恶性肿瘤风险增加,ECD肾移植的老年受者是一个特殊人群,需要量身定制的免疫抑制方案。ECD肾脏受者通常被排除在移植试验之外,因此,他们的最佳诱导和维持免疫抑制方案尚不清楚。方法在很大程度上因中心而异,且基于专家意见。一些数据表明,抗胸腺细胞球蛋白可能是ECD肾脏老年受者的首选诱导剂。有人主张采用避免使用CNI的维持方案,特别是对于ECD肾脏的老年受者。由于偶尔出现较高的排斥率,无CNI方案并未得到普遍认可。然而,基于雷帕霉素靶蛋白抑制剂的减少CNI暴露和无CNI方案,在适当选择的ECD移植受者中已显示出可接受的结果。